Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biocorrx Inc (OP: BICX ) 0.7800 -0.0300 (-3.70%) Streaming Delayed Price Updated: 11:03 AM EDT, May 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,936 Open 0.7800 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.8100 Today's Range 0.7800 - 0.7800 52wk Range 0.6720 - 2.220 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BioCorRx Reports Business Update for the First Quarter of 2024 May 16, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Death Intellectual Property Exposures Death Intellectual Property BioCorRx Reports Business Update for the First Quarter of 2024 May 16, 2024 ANAHEIM, CA - (NewMediaWire) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today... Via TheNewswire.com Topics Death Intellectual Property Exposures Death Intellectual Property Performance YTD +7.59% +7.59% 1 Month -4.88% -4.88% 3 Month -6.70% -6.70% 6 Month -35.67% -35.67% 1 Year -60.61% -60.61% More News Read More BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia April 03, 2024 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia April 03, 2024 Via TheNewswire.com Topics Intellectual Property Exposures Intellectual Property BioCorRx Reports Business Update for 2023 April 02, 2024 Via NewMediaWire Topics Death Exposures Death BioCorRx Reports Business Update for 2023 April 02, 2024 Via TheNewswire.com Topics Death Exposures Death BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD February 28, 2024 Via NewMediaWire BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD February 28, 2024 Via TheNewswire.com Topics Death Exposures Death BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors February 08, 2024 Via NewMediaWire BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors February 08, 2024 Via TheNewswire.com Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying January 18, 2024 Via Benzinga Topics Stocks Exposures US Equities BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President January 09, 2024 Via NewMediaWire BioCorRx Reports Business Update for the Third Quarter of 2023 November 14, 2023 Via NewMediaWire Topics Death Exposures Death BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder August 15, 2023 Via NewMediaWire Exposures Product Safety BioCorRx Reports Business Update for the Second Quarter of 2023 August 14, 2023 Via NewMediaWire Exposures Product Safety BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder July 18, 2023 Via NewMediaWire Topics Death Exposures Death Product Safety Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying July 07, 2023 Via Benzinga BioCorRx Provides Business Update for the First Quarter of 2023 May 16, 2023 Via NewMediaWire BioCorRx Provides Business Update for 2022 April 03, 2023 Via NewMediaWire BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting March 07, 2023 Via NewMediaWire BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data February 23, 2023 Via NewMediaWire Exposures Product Safety BioCorRx to Present at Sequire Biotechnology Conference on February 2nd January 27, 2023 Via NewMediaWire BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors January 24, 2023 Via NewMediaWire BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder January 19, 2023 Via NewMediaWire Clear Channel Outdoor, Archer Aviation And These 2 Stocks Under $3 Insiders Are Aggressively Buying January 18, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
